Evidence map›Paper›PMID 29239517›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2017

Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.

Ashley V Kroll, Ronnie H Fang, Yao Jiang, Jiarong Zhou, Xiaoli Wei, Chun Lai Yu, Jie Gao, Brian T Luk, Diana Dehaini, Weiwei Gao and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed
16.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 496 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.ACS applied materials & interfaces · 2025
    Review
  18. Review
  19. Review
  20. Review

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ashley V KrollDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Yao JiangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Jiarong ZhouDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Xiaoli WeiDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Chun Lai YuDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Jie GaoDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Brian T LukDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Diana DehainiDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Weiwei GaoDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, San Diego, La Jolla, CA, 92093, USA.ORCID http://orcid.org/0000-0003-0637-0654
University of California San Diego · US

Funding

Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma MetastasisR01CA200574 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LI, SHULIN, ZHANG, LIANGFANG · 2016 to 2020
$1.8M
Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
Chemical Biology Interfaces at UC San DiegoT32GM112584 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BURKART, MICHAEL D. · 2015 to 2019
$729k
NCI NIH HHS R01 CA200574NCI NIH HHS T32 CA153915NIGMS NIH HHS T32 GM112584
6 · The paper itself

Abstract

Anticancer vaccines train the body's own immune system to recognize and eliminate malignant cells based on differential antigen expression. While conceptually attractive, clinical efficacy is lacking given several key challenges stemming from the similarities between cancerous and healthy tissue. Ideally, an effective vaccine formulation would deliver multiple tumor antigens in a fashion that potently stimulates endogenous immune responses against those antigens. Here, it is reported on the fabrication of a biomimetic, nanoparticulate anticancer vaccine that is capable of delivering autologously derived tumor antigen material together with a highly immunostimulatory adjuvant. The two major components, tumor antigens and adjuvant, are presented concurrently in a fashion that maximizes their ability to promote effective antigen presentation and activation of downstream immune processes. Ultimately, it is demonstrated that the formulation can elicit potent antitumor immune responses in vivo. When combined with additional immunotherapies such as checkpoint blockades, the nanovaccine demonstrates substantial therapeutic effect. Overall, the work represents the rational application of nanotechnology for immunoengineering and can provide a blueprint for the future development of personalized, autologous anticancer vaccines with broad applicability.

Indexed as

Cell MembraneAntigens, NeoplasmCancer VaccinesHumansImmunotherapyNanostructuresNeoplasmsAntigens, NeoplasmCancer Vaccinesanticancer vaccinesbiomimetic nanoparticlesimmunotherapiesnanomedicinespersonalized medicines

Identifiers

PMID29239517
PMCPMC5794340
OpenAlexW2765097474

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.